Drug Profile
Permethrin foam
Alternative Names: PerFoamFive; PerFoamOne; Permethrin foam - FoamixLatest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator Foamix
- Class Antiparasitics; Pyrethrins; Small molecules
- Mechanism of Action Sodium channel agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Discontinued Pediculosis; Scabies
Most Recent Events
- 09 Mar 2020 Foamix has been acquired by Menlo Therapeutics
- 02 May 2013 Clinical development is ongoing in Israel
- 22 Sep 2010 Taro Pharmaceutical Industries has been acquired by Sun Pharmaceutical Industries